Effectiveness of ivermectin-based multidrug therapy in severely hypoxic, ambulatory COVID-19 patients

• Published in: Future microbiology Vol. 17; no. 5; pp. 339 - 350
• Main Authors: Hazan, Sabine, Dave, Sonya, Gunaratne, Anoja W, Dolai, Sibasish, Clancy, Robert L, McCullough, Peter A, Borody, Thomas J
• Format: Journal Article
• Language: English
• Published: England Future Medicine Ltd 01.03.2022
• Subjects: coronavirus; COVID; COVID-19 Drug Treatment; doxycycline; Drug Therapy, Combination; Humans; Hypoxia - drug therapy; ivermectin; Ivermectin - therapeutic use; Leprostatic Agents - therapeutic use; SARS-CoV-2; Short Communication; Treatment Outcome; zinc; COVID; coronavirus; SARS-CoV-2; doxycycline; ivermectin; zinc
• ISSN: 1746-0913; 1746-0921; 1746-0921
• DOI: 10.2217/fmb-2022-0014

Ivermectin is a safe, inexpensive and effective early COVID-19 treatment validated in 20+ random, controlled trials. Having developed combination therapies for , the authors present a highly effective COVID-19 therapeutic combination, stemming from clinical observations. In 24 COVID-19 subjects refusing hospitalization with high-risk features, hypoxia and untreated moderate to severe symptoms averaging 9 days, the authors administered this novel combination of ivermectin, doxycycline, zinc and vitamins D and C. All subjects resolved symptoms (in 11 days on average), and oxygen saturation improved in 24 h (87.4% to 93.1%; p = 0.001). There were no hospitalizations or deaths, less than (p < 0.002 or 0.05, respectively) background-matched CDC database controls. Triple combination therapy is safe and effective even when used in outpatients with moderate to severe symptoms. NCT04482686 ( )